KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Equity (2016 - 2025)

Historic Return on Equity for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to 0.54%.

  • Xenon Pharmaceuticals' Return on Equity fell 2800.0% to 0.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54%, marking a year-over-year decrease of 2800.0%. This contributed to the annual value of 0.29% for FY2024, which is 700.0% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Return on Equity stood at 0.54%, which was down 2800.0% from 0.44% recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Return on Equity ranged from a high of 0.14% in Q2 2022 and a low of 0.54% during Q3 2025
  • Its 5-year average for Return on Equity is 0.25%, with a median of 0.23% in 2024.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Return on Equity surged by 1100bps in 2022, and later crashed by -2800bps in 2025.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Return on Equity stood at 0.2% in 2021, then increased by 14bps to 0.17% in 2022, then plummeted by -37bps to 0.23% in 2023, then tumbled by -37bps to 0.32% in 2024, then tumbled by -68bps to 0.54% in 2025.
  • Its last three reported values are 0.54% in Q3 2025, 0.44% for Q2 2025, and 0.36% during Q1 2025.